Word

MORPHOSYS

Status

Registered

Status Code

700

Status Date

Tuesday, June 6, 2023

Serial Number

97042228

Registration Number

7071326

Registration Date

Tuesday, June 6, 2023

Mark Type

4000

Filing Date

Thursday, September 23, 2021

Published for Opposition

Tuesday, March 21, 2023

Trademark Owner History

MorphoSys AG - Original Registrant

Classifications

5 pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules for the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; small molecule compounds for use as drug delivery agents in pharmaceuticals; small molecule compounds being pharmaceuticals for the treatment and prevention of diseases and disorders, namely, metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis in humans; small molecule pharmaceuticals for the treatment of diseases and conditions, namely, metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; Pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely, metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; antibodies sold as a component ingredient of pharmaceuticals for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; Clinical medical reagents; Biological preparations for medical purposes, namely, for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; pharmaceutical and veterinary preparations, agents and substances for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis

1 reagents for scientific and medical research for use in the research and production of small molecule pharmaceuticals; active pharmaceutical ingredients, namely, antibodies, proteins and small molecules for use in the manufacture of pharmaceuticals, biopharmaceuticals, vaccines, and finished drug products; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines

42 Pharmaceutical research and development of pharmaceutical preparations, medicines and vaccines; providing medical and scientific research information; Scientific research in the nature of conducting clinical trials for others; scientific and technological services, namely, scientific research, analysis, and testing services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; research and design services, namely, research and development in the field of antibodies and clinical research in connection with the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis

Trademark Events

Jun 6, 2023

Notice Of Registration Confirmation Emailed

Jun 6, 2023

Registered-Principal Register

Mar 21, 2023

Official Gazette Publication Confirmation E-Mailed

Mar 21, 2023

Published For Opposition

Mar 1, 2023

Notification Of Notice Of Publication E-Mailed

Feb 13, 2023

Approved For Pub - Principal Register

Feb 10, 2023

Examiner's Amendment Entered

Feb 10, 2023

Notification Of Examiners Amendment E-Mailed

Feb 10, 2023

Examiners Amendment E-Mailed

Feb 10, 2023

Examiners Amendment -Written

Feb 1, 2023

Examiner's Amendment Entered

Feb 1, 2023

Notification Of Examiners Amendment E-Mailed

Feb 1, 2023

Examiners Amendment E-Mailed

Feb 1, 2023

Examiners Amendment -Written

Jan 10, 2023

Teas/Email Correspondence Entered

Jan 10, 2023

Correspondence Received In Law Office

Jan 9, 2023

Assigned To Lie

Nov 11, 2022

Teas Response To Office Action Received

Jun 27, 2022

Notification Of Non-Final Action E-Mailed

Jun 27, 2022

Non-Final Action E-Mailed

Jun 27, 2022

Non-Final Action Written

Jun 24, 2022

Assigned To Examiner

Oct 25, 2021

New Application Office Supplied Data Entered

Sep 27, 2021

New Application Entered